Bayer Net Income 2010-2023 | BAYRY

Bayer net income from 2010 to 2023. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Bayer Annual Net Income
(Millions of US $)
2023 $-3,183
2022 $4,372
2021 $1,183
2020 $-11,988
2019 $4,582
2018 $2,002
2017 $8,292
2016 $5,014
2015 $4,564
2014 $4,554
2013 $4,236
2012 $3,146
2011 $3,443
2010 $1,728
2009 $1,895
Bayer Quarterly Net Income
(Millions of US $)
2023-12-31 $1,510
2023-09-30 $-4,973
2023-06-30 $-2,058
2023-03-31 $2,338
2022-12-31 $446
2022-09-30 $550
2022-06-30 $-317
2022-03-31 $3,693
2021-12-31 $1,369
2021-09-30 $100
2021-06-30 $-2,805
2021-03-31 $2,518
2020-12-31 $90
2020-09-30 $-3,208
2020-06-30 $-10,513
2020-03-31 $1,643
2019-12-31 $1,566
2019-09-30 $1,152
2019-06-30 $454
2019-03-31 $1,410
2018-12-31 $-4,709
2018-09-30 $3,356
2018-06-30 $953
2018-03-31 $2,402
2017-12-31 $774
2017-09-30 $4,561
2017-06-30 $1,346
2017-03-31 $1,610
2016-12-31 $464
2016-09-30 $1,325
2016-06-30 $1,559
2016-03-31 $1,667
2015-12-31 $707
2015-09-30 $1,111
2015-06-30 $1,274
2015-03-31 $1,471
2014-12-31 $201
2014-09-30 $1,096
2014-06-30 $1,307
2014-03-31 $1,950
2013-12-31 $634
2013-09-30 $971
2013-06-30 $1,098
2013-03-31 $1,532
2012-12-31 $474
2012-09-30 $661
2012-06-30 $635
2012-03-31 $1,377
2011-12-31 $534
2011-09-30 $909
2011-06-30 $1,075
2011-03-31 $935
2010-12-31 $-199
2010-09-30 $361
2010-06-30 $670
2010-03-31 $914
2009-12-31 $219
2009-09-30 $373
2009-06-30 $725
2009-03-31 $556
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $0.000B $51.553B
Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses. The company started reporting in three segments ' Pharmaceuticals, Consumer Health and Crop Science ' from the third quarter of 2019. Both Animal Health and Currenta were reported as discontinued operations in the quarter. The company acquired U.S. seed giant Monsanto in June, 2018. With the acquisition, Bayer now has the strongest portfolio of seed and crop protection products for a wide range of crops and indications, the best research and development platform and the leading digital farming business.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $688.746B 114.69
Novo Nordisk (NVO) Denmark $564.487B 46.50
Johnson & Johnson (JNJ) United States $353.804B 14.04
Merck (MRK) United States $331.117B 60.24
AbbVie (ABBV) United States $296.212B 15.06
AstraZeneca (AZN) United Kingdom $232.626B 20.22
Novartis AG (NVS) Switzerland $202.479B 14.36
Pfizer (PFE) United States $143.036B 13.80
Sanofi (SNY) $124.861B 11.78
Innoviva (INVA) United States $0.948B 6.69